Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

GRF PEER ANALYSIS

Grifols S.A. — metric-by-metric comparison with peers and the industry median

GRFGrifols S.A.

🇪🇸 Spain · MC · Healthcare · Drug Manufacturers - General

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Drug Manufacturers - General

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial HealthDividend
GRFIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
GRF-13.3%AZN+38.8%OGN+37.3%AZN+36.0%BIIB+56.9%GSK+46.5%
Year-to-Date (YTD)
GRF-15.3%AZN+3.3%OGN+89.9%AZN+7.5%BIIB+18.4%GSK+10.6%
1-Year
Split-adjusted
GRF-13.3%ROVI+3.0%
Year-to-Date (YTD)
GRF-15.3%ROVI-10.1%

Key Metric Comparison

P/E

Lower is better
GRF14.86AZN28.08OGN14.49AZN28.27BIIB22.54GSK13.86Median 22.54

ROE

Higher is better
GRF7.5%AZN23.7%OGN34.0%AZN23.5%BIIB7.7%GSK36.4%Median 23.7%

Net Margin

Higher is better
GRF5.6%AZN17.2%OGN4.0%AZN17.2%BIIB13.9%GSK17.8%Median 15.0%

Revenue Growth

Higher is better
GRF0.9%AZN9.7%OGN-2.1%AZN9.9%BIIB0.4%GSK4.0%Median 3.3%

P/E

Lower is better
GRF14.86ROVI22.16Median 22.54

ROE

Higher is better
GRF7.5%ROVI20.9%Median 23.7%

Net Margin

Higher is better
GRF5.6%ROVI17.8%Median 15.0%

Revenue Growth

Higher is better
GRF0.9%ROVI-3.4%Median 3.3%

All Metrics

Valuation
MetricGRFAZNOGNAZNBIIBGSKInd. Median
P/E14.8628.0814.4928.2722.5413.86●22.54
P/B1.13●6.203.956.201.664.534.53
EV/EBITDA10.5315.577.97●15.6912.298.3413.48
P/S0.834.830.58●4.863.142.463.14
Financial Health
MetricGRFAZNOGNAZNBIIBGSKInd. Median
Current Ratio2.470.911.970.913.06●0.791.25
Debt/Equity177.2%71.7%948.9%71.7%35.2%●106.7%94.3%
NetDebt/EBITDA6.221.285.391.290.84●1.351.35
Profitability
MetricGRFAZNOGNAZNBIIBGSKInd. Median
Net Margin5.6%17.2%4.0%17.2%13.9%17.8%●15.0%
ROE7.5%23.7%34.0%23.5%7.7%36.4%●23.7%
ROA2.0%9.5%●1.9%9.4%4.8%9.4%8.0%
EBITDA Margin19.3%33.8%22.4%33.7%27.4%35.3%●28.4%
Growth + Dividend
MetricGRFAZNOGNAZNBIIBGSKInd. Median
Rev. Growth0.9%9.7%-2.1%9.9%●0.4%4.0%3.3%
NI Growth112.7%●32.9%-67.2%33.7%-7.2%84.9%32.9%
Div. Yield2.1%2.2%0.6%0.2%—3.3%●2.1%
Payout30.8%47.0%8.9%47.3%—44.5%45.7%
Valuation
MetricGRFROVIInd. Median
P/E14.86●22.1622.54
P/B1.13●4.334.53
EV/EBITDA10.53●14.6913.48
P/S0.83●3.943.14
Financial Health
MetricGRFROVIInd. Median
Current Ratio2.473.66●1.25
Debt/Equity177.2%17.0%●94.3%
NetDebt/EBITDA6.220.09●1.35
Profitability
MetricGRFROVIInd. Median
Net Margin5.6%17.8%●15.0%
ROE7.5%20.9%●23.7%
ROA2.0%15.1%●8.0%
EBITDA Margin19.3%27.0%●28.4%
Growth + Dividend
MetricGRFROVIInd. Median
Rev. Growth0.9%●-3.4%3.3%
NI Growth112.7%●-5.9%32.9%
Div. Yield2.1%●1.6%2.1%
Payout30.8%36.3%45.7%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on GRF

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.